Symic Biomedical

Developer of compounds to protect against tissue degradation and promote healing during illness or injury

placeSan Francisco, California, United States calendar_todayFounded 2012 groups2 employees language symic.bio

Innovation

7 patent families (2 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace dormant. Cited 499 times.

YearFilings
20142
20155
20164
20172

Investor mix

16 investors on record; lead investors include Cell Innovation Partners, HEDA Ventures, Lilly Ventures.

Investor typeCountShare
Venture capital956%
Private equity16%
Accelerator & incubator319%
Other / undisclosed319%
Coming soon